retatrutide type 2 diabetes phase 2 trial results 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic 💉 A triple-action once-weekly injection

At Klinic, Zepbound is prescribed for adults aged 18 and up

, , 6 -

It is such a sad thing to sit next to my loved one, and she'll say to me, "I know my brain's not working right." Like, she knows enough to know that she's not processing information in a way that she used to and it's really disappointing and upsetting, and it's devastating quite honestly, because she's a lovely person, but she's not who she was before because of this progressive neurocognitive decline

A more significant concern is the increased risk of hypoglycemia (low blood sugar), especially if other glucose-lowering medications are also being used

These results demonstrate superior performance compared to other GLP-1 agonists, insulin, and placebo [23, 24, 25, 26]